
Opinion|Videos|January 1, 2025
Discussing Seladelpar as a Potential Therapeutic for PBC
Panelists discuss how seladelpar showed remarkable efficacy in the RESPONSE trial, demonstrating significant improvements in alkaline phosphatase levels and other biochemical markers compared with placebo.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Seladelpar has been studied extensively, with the
RESPONSE trial serving as one of its landmark studies. What are the key efficacy findings from this trial?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Clots, Catheters, and Clinical Pearls: Pulmonary Embolism Updates for Practicing Pharmacists
2
Cyclosporiasis on the Rise in the United States, Exceeding 450 Cases
3
Medicare's New GLP-1 Bridge Program: What Pharmacists Need to Know Before Dispensing
4
GLP-1 RAs Linked to Lower Mortality, Amputation Risk in Patients With PAD and Type 2 Diabetes
5









































































































